Tianda Pharmaceuticals (HKSE:00455) Debt-to-Equity : 0.19 (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is Tianda Pharmaceuticals Debt-to-Equity?

Tianda Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$102.2 Mil. Tianda Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$11.4 Mil. Tianda Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$592.1 Mil. Tianda Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was 0.19.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Tianda Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

HKSE:00455' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 0.19 Max: 0.21
Current: 0.19

During the past 13 years, the highest Debt-to-Equity Ratio of Tianda Pharmaceuticals was 0.21. The lowest was 0.04. And the median was 0.19.

HKSE:00455's Debt-to-Equity is ranked better than
60.85% of 848 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs HKSE:00455: 0.19

Tianda Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Tianda Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianda Pharmaceuticals Debt-to-Equity Chart

Tianda Pharmaceuticals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.04

0.19

0.21

0.19

Tianda Pharmaceuticals Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.22	0.21	0.25	0.18	0.19

Competitive Comparison of Tianda Pharmaceuticals's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Tianda Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tianda Pharmaceuticals's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tianda Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Tianda Pharmaceuticals's Debt-to-Equity falls into.

Tianda Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Tianda Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(102.17	+	11.427)	/	592.071
	=	0.19

Tianda Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(102.17	+	11.427)	/	592.071
	=	0.19

Tianda Pharmaceuticals (HKSE:00455) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Tianda Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Tianda Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Tianda Pharmaceuticals (HKSE:00455) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianda Pharmaceuticals Ltd (HKSE:00455) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

CITIC Tower, No. 1 Tim Mei Avenue, Suites 2405-2410, 24th Floor, Central, Hong Kong, HKG

Website

https://www.tiandapharma.com

Tianda Pharmaceuticals Ltd is engaged in R&D, manufactures and sales of pharmaceutical, biotechnology and healthcare products. The group also engages in R&D of Chinese medicine and manufacture and sales of Chinese medicine products, and the provision of Chinese medical services. Its operating segments include Chinese medicine business; Medical and healthcare services; and Pharmaceuticals and medical technologies business. The company derives majority of the revenue from Pharmaceuticals and medical technologies business.

Executives

Tianda Group Limited	2101 Beneficial owner
Fang Wen Quan	2201 Interest of corporation controlled by you

Tianda Pharmaceuticals (HKSE:00455) Headlines

No Headlines